NCT07040228View on ClinicalTrials.gov

A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 26, 2025

Primary Completion Date

May 30, 2027

Study Completion Date

May 30, 2027

Conditions
Pancreatic Cancer Metastatic
Interventions
DRUG

Regorafenib combined with Toripalimab and Albumin paclitaxel

Regorafenib combined with Toripalimab and Albumin paclitaxel as the third line treatment for patients with advanced pancreatic cancer

Trial Locations (1)

518000

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen

All Listed Sponsors
collaborator

Qilu Pharmaceutical Group Co., Ltd

UNKNOWN

collaborator

Shanghai Junshi Biomedical Technology Co., Ltd

UNKNOWN

lead

Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center

OTHER